The logos of Danish drugmaker Novo Nordisk, shaper of the blockbuster diabetes and weight-loss treatments Ozempic and Wegovy is seen extracurricular theri gathering arsenic the institution presents the yearly study astatine Novo Nordisk successful Bagsvaerd, Denmark, connected February 5, 2025.
Mads Claus Rasmussen | Afp | Getty Images
Metsera connected Tuesday said Novo Nordisk's caller bid for the obesity biotech is "superior" to a revised offer from Pfizer, escalating a heated tussle implicit the startup betwixt the 2 pharmaceutical giants.
Novo Nordisk's caller connection values Metsera astatine up to $86.20 per share, for a full of astir $10 billion. In a release, Metsera said that represents a astir 159% premium to its closing terms arsenic of Sept. 19, the past trading time earlier Pfizer announced its proposed acquisition of the company.
Meanwhile, Pfizer's caller connection values Metsera astatine up to $70 per share, for a full of astir $8.1 billion.
The caller bids comes 1 time aft Pfizer filed its 2nd lawsuit against Novo Nordisk and Metsera, alleging that the Danish drugmaker's effort to outbid Pfizer to get the biotech institution is anticompetitive.
The clash reflects the shifting scenery for blockbuster value nonaccomplishment and diabetes drugs, with seasoned Novo Nordisk present trailing rival Eli Lilly arsenic different companies similar Pfizer contention to interruption in.
For Pfizer, Metsera's pipeline could beryllium the company's aureate summons to participate the abstraction aft struggling to bring its ain obesity products to marketplace implicit the past fewer years. Novo Nordisk helped found the market, but is losing marketplace stock to Eli Lilly and cheaper copycats and struggling to impressment investors with its cause pipeline.
This is breaking news. Please refresh for updates.
English (US) ·